A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3064-3064 ◽  
Author(s):  
A. Daud ◽  
G. M. Springett ◽  
D. S. Mendelson ◽  
P. N. Munster ◽  
J. W. Goldman ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Selective Inhibitor ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study ◽  
Checkpoint Kinase ◽  
Checkpoint Kinase 1

A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e17049-e17049 ◽  
Author(s):  
Jason D. Lickliter ◽  
Hui Kong Gan ◽  
Tarek Meniawy ◽  
Jason Yang ◽  
Lai Wang ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Selective Inhibitor ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

2012 ◽  
Vol 18 (9) ◽  
pp. 2658-2667 ◽  
Author(s):  
Klaus Mross ◽  
Annette Frost ◽  
Simone Steinbild ◽  
Susanne Hedbom ◽  
Martin Büchert ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

2009 ◽  
Vol 66 (4) ◽  
pp. 669-680 ◽  
Author(s):  
Francisco Robert ◽  
Alan Sandler ◽  
Joan H. Schiller ◽  
Glenn Liu ◽  
Karen Harper ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors

2014 ◽  
Vol 74 (5) ◽  
pp. 917-925 ◽  
Author(s):  
Carlos R. Becerra ◽  
Paul Conkling ◽  
Nicholas Vogelzang ◽  
Hilary Wu ◽  
Shengyan Hong ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

2014 ◽  
Vol 20 (18) ◽  
pp. 4747-4757 ◽  
Author(s):  
Paul Haluska ◽  
Michael Menefee ◽  
Elizabeth R. Plimack ◽  
Jonathan Rosenberg ◽  
Donald Northfelt ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study
Sign in / Sign up

Export Citation Format

Share Document